KRYS - クリスタル・バイオテック (Krystal Biotech Inc.) クリスタル・バイオテック

 KRYSのチャート


 KRYSの企業情報

symbol KRYS
会社名 Krystal Biotech Inc (クリスタル・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Krystal Biotech Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform or STAR-D platform that consists of a patent pending engineered viral vector based on herpes simplex virus 1 or HSV-1 and skin-optimized gene transfer technology to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company''s KB103 is in preclinical development to treat dystrophic epidermolysis bullosa or DEB a rare and severe genetic disease. The Company''s KB104 is to treat Netherton Syndrome a severe form of ichthyosis which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation itchiness and dehydration.   クリスタル・バイオテックは米国のバイオ医薬品企業。主に皮膚疾患に対する遺伝子治療の開発・商業化に従事する。同社はHSV-1に基づくウィルスベクタ―と皮膚最適化遺伝子導入技術プラットフォ―ム「STAR-D」を開発。重度の遺伝病であるジストロフィ―性表皮水疱症に対する遺伝子治療「KB-103」を開発する。本社所在地はペンシルベニア州ピッツバ―グ。   
本社所在地 2100 Wharton Street Suite 701 Pittsburgh PA 15203 USA
代表者氏名
代表者役職名
電話番号 +1 412-586-5830
設立年月日 42339
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数
url www.krystalbio.com
nasdaq_url https://www.nasdaq.com/symbol/krys
adr_tso
EBITDA EBITDA(百万ドル) -8.25600
終値(lastsale) 15.51
時価総額(marketcap) 170282987.16
時価総額 時価総額(百万ドル) 234.93030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 189.48030
当期純利益 当期純利益(百万ドル) -11.09200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Krystal Biotech Inc revenues was not reported. Net loss increased from $1.3M to $4.4M. Higher net loss reflects Research and Development - Balancing increase from $698K to $2.9M (expense) General and Administrative - Balancing increase from $347K to $1.6M (expense) Stock-based Compensation in R&D increase of 82% to $122K (expense).

 KRYSのテクニカル分析


 KRYSのニュース

   JonesTrading Stick to Their Buy Rating for Krystal Biotech Inc By Investing.com  2021/03/01 19:05:01 Investing.com
JonesTrading Stick to Their Buy Rating for Krystal Biotech Inc
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock  2021/02/02 21:10:00 Business Wire
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock. The Company intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to wheth
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.
   Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock  2021/02/02 21:10:00 Business Wire
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock. The Company intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to wheth
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa  2021/01/22 12:22:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Merus NV (NASDAQ: MRUS ) Neuronetics Inc (NASDAQ: STIM ) OncoSec Medical Inc (NASDAQ: ONCS ) (announced common stock offering) PRA Health Sciences Inc (NASDAQ: PRAH ) Precision BioSciences Inc (NASDAQ: DTIL ) Profound Medical Corp (NASDAQ: PROF ) Renalytix AI PLC (NASDAQ: RNLX ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Surface Oncology Inc (NASDAQ: SURF ) Syneos Health Inc (NASDAQ: SYNH ) Synlogic Inc (NASDAQ: SYBX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.
   H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc By Investing.com  2021/01/08 11:26:08 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc
   H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc By Investing.com  2021/01/08 11:26:08 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc
   Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors  2021/01/04 13:00:00 Business Wire
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L. Marantz, MD, PhD, MBA to its board of directors. “We are pleased to welcome Drs. Mason and Marantz to our board of directors,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. “They bring significant gene therapy translational and rare diseas
   Krystal Biotech to Present at the Evercore ISI HealthCONx Conference  2020/11/24 13:00:00 Business Wire
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd Annual HealthCONx virtual conference taking place December 1-3, 2020. Details for the webcast are as follows: Evercore ISI 3rd Annual HealthCONx virtual conference Presentation Date: Tuesday, December 1, 2020 Presentation Ti
   Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress  2020/11/09 13:00:00 Business Wire
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today reported financial results and key operational progress updates for the third quarter ended September 30, 2020. “Despite the challenges presented by COVID in this quarter, we initiated a pivotal trial for DEB, a phase 2 trial in ARCI and a phase 1 trial in aesthetic skin conditions, and I thank
   Krystal Biotech Inc (NASDAQ:KRYS) Given Consensus Recommendation of “Buy” by Analysts  2020/10/24 00:30:42 US Banking News
Shares of Krystal Biotech Inc (NASDAQ:KRYS) have been assigned an average rating of “Buy” from the nine brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokers that have […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリスタル・バイオテック KRYS Krystal Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)